Gedea Biotech completes VVC-2025 study and advances product expansion to treat vaginal fungal infections
Gedea Biotech today announced continued progress in its strategy to expand the CE-marked indications for pHyph to include the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal fungal infection. The company has completed the clinical study, VVC-2025 and continues to advance the review process for ex…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Diaverum opens its first renal care clinic in Bishkek, Kyrgyzstan
- Global Industry Leaders Chart the Future of Agentic Commerce and AI-Driven Search
- Observe Medical Launches New Website to Strengthen Dialogue with Healthcare Decision-Makers Around Innovative UnoMeter™ Safeti™ Max
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →